肝细胞生长因子与特发性肺纤维化

特发性肺纤维化（idiopathic pulmonary fibrosis，IPF）是一种原因不明的慢性肺部疾患，以肺间质纤维化为主要特征，其发病隐匿，进展迅速，病死率高。从发病后到死亡，IPF患者的平均生存时间为3～5年。目前对于IPF的治疗仍然是以糖皮质激素和免疫抑制剂药物为主，但疗效不佳。已有的研究表明：糖皮质激素治疗1PF的有效率小于30％，合用免疫抑制剂后不但会引起严重的不良反应，而且也不能有效降低IPF患者的病死率。这些都似乎说明炎细胞的浸润并不是导致IPF发病的原因，而是继发于IPF的一种炎症反应。随着对IPF发病机制研究的不断深入，许多新的治疗方法与药物正逐步受到医学界的重视，肝细胞生长因子（hepatocyte growth factor，HGF）便是其中一种。本文概述了近年来对HGF在IPF治疗中的研究进展。

Hepatocyte growth factor and idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis(IPF),a type of cryptogenic chronic pulmonary disease characterized with dormant onset,rapid progress and high mortality rate,represents itself mainly by pulmonary interstitial fibrosis.The average life span of sufferers ranges from 3 to 5 years since onset.Current therapeutic measures against IPF is primarily limited to the application of glucocorticoid and immunosuppressor but without ideal effect.Existed data suggested that the effective rate of therapy with glucocorticoid against IPF is below 30%;moreover,high mortality rate remained as it was but serious side effects came out when immunosuppressor was added.These observations suggest that the infiltration of inflammatory cells is not pathogen of IPF,but secondary inflammatory response of IPF.Numerous novel therapeutic methods and drugs against IPF are being taken into account along with gradually increased understanding of nosogenesis of IPF,such as the application of hepatocyte growth factor(HGF).Here,therapeutic strategies with HGF against IPF introduced recently are reviewed.